Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2023-09-01 10:18 am Purchase | 2023-08-22 | 13G | Puma Biotechnology, Inc. PBYI | ACORN BIOVENTURES, L.P. | 2,739,935 5.800% | 2,739,935 (New Position) | Filing History |
| 2023-04-27 12:11 pm Purchase | 2023-04-20 | 13G | BioAtla, Inc. BCAB | ACORN BIOVENTURES, L.P. | 2,726,455 5.700% | 2,726,455 (New Position) | Filing History |
| 2023-04-03 1:46 pm Purchase | 2023-03-15 | 13G | Y-mAbs Therapeutics, Inc. YMAB | ACORN BIOVENTURES, L.P. | 2,326,528 5.300% | 2,326,528 (New Position) | Filing History |
| 2023-01-26 1:36 pm Purchase | 2022-12-31 | 13G | Cyclacel Pharmaceuticals, Inc. CYCC | ACORN BIOVENTURES, L.P. | 782 9.990% | 131 (+20.07%) | Filing History |
| 2023-01-26 1:30 pm Unchanged | 2023-01-26 | 13G | Cardiff Oncology, Inc. CRDF | ACORN BIOVENTURES, L.P. | 3,043,173 6.380% | 0 (Unchanged) | Filing History |
| 2023-01-26 1:28 pm Sale | 2022-09-13 | 13D | Cardiff Oncology, Inc. CRDF | ACORN BIOVENTURES, L.P. | 3,043,173 6.380% | -2,947,666 (-49.20%) | Filing History |
| 2022-12-05 4:30 pm Purchase | 2022-11-23 | 13G | OptiNose, Inc. OPTN | ACORN BIOVENTURES, L.P. | 757,931 9.900% | 757,931 (New Position) | Filing History |
| 2021-02-12 4:58 pm Purchase | 2020-12-18 | 13G | Cyclacel Pharmaceuticals, Inc. CYCC | ACORN BIOVENTURES, L.P. | 651 9.990% | 651 (New Position) | Filing History |